home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  August 11, 2022
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [7] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 429 active entries

Immuno Life Info Canada

-/ 1440 Barberry Dr. PT COQ BC V3B1G3 CA
Toll free: +011-604-941-9022 (help line)

Phone: +011-604-945-8408 (landline)
Fax: +011-604-941-9022 (FAX line)
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it


Perspectives for Developmental Biology & Physiology: to

establish the basis with Cell Molecular Biology


The use of a unified approach in Developmental Biology or Physiology at the cellular level to undertake the understanding of the basis of all cellular phenomena from the: cell's life span and longevity; cellular repair and remission from diseased states; growth and development, energetics, efficiency and productivity; and activatable states for therapeutic applications (e. g. anti-viral therapies) is becoming a reality.

Research Areas we are pursuing that are sourced from our own experiments and the scientific literature:

  • Models to study are cell activatable therapeutics (CATs) and the immune system using experimental sheep modeling (e. g. a novel schema for neuro-immunotargeting cancers).
  • The lower molecular weight [LMW] proteome and new pharma to discover with musco-regulatory factors (MRFs) and muscle tissue development and regulation for productive end products and health.
  • The use of lithium and umbilical cord blood cells to restore function in chronic complete spinal cord injury.
  • Speculation for a role with energy efficiency utilization at the cellular level and the role of p38 and tissue necrotic factors alpha (TNF-alpha) and mitogenesis and longevity or lifespan. There is research continuing in this area at the Medical Faculty, UNSW, Sydney, Australia NSW 2033.
  • VitD and fructan and their interactions with p38 and their role in modulating the low-intensity, chronic inflammatory response as it impacts disease states such as: atherosclerosis, T2Diabetes, hypertension, and multiple sclerosis with new pharma to be discovered.
  • Fructan and APPs and their role in determining the efficiency of microbial biomass turnover in the ungulate stomach; this as a model has also applications to efficiency in productivity of farming animals and should be of interest at the U. of New England, Armidale NSW (AU) 2351 in their Large Animal Research Unit (LARU) for energetics livestock research in future.
  • Immunocontrol in the rumen such as with predators and enteropathogens; cell membrane and porin modeled biocontainment of probiotics in the rumen stomach using recombinant technology; and dsRNA technology with PCS delivery systems in adjuvant with feeds and rumen digestion; opening up is a dairy application with mastitic control in the boosted (GMO) or hi-producing cow's udder. 
  • There is a question of what therapeutic modalities, viz. including genetic counselling & therapy with stem cell transplantation therapy that will emerge from research of this vast, new area encompassing cell development & physiology and its attendant pharma especially from the mind-body axies (e. g. brain<->organosomal systems and others with interlinks) to be discovered in the analysis of the depleted plasmoidal and plasmoidal-like LMW-proteome.

This therapeutic approach has recently been introduced in actual research and is undergoing evaluation as to its efficacy. We will be reporting on this topic as it unfolds with new developments.
Recently reports from specific cases in clinical trials involving T-cell targeted immunity against non-Hodgkins lymphoma cancerous blood cells proved to bring about remission in treated patients over a 2 yr period. 
Fig. 1. New Perspectives in Immunomodulation:  Neuro-Immuno targeting with Cancers Using Cell-Based Therapies.
A. Adaptive Immunity:
    Putative Neurhormones
                  AR (=adrenoreceptors)
                  DC (=dendritic cells)
                  |   |
                  |   |
                  |   |
                  |   |
                  |   - -------------------> 1) Complement----- -
                  |                                   Opsonization       |
                  |                                                               |--->  Apoptosis with Multiple Solid Tumours /
                  |                                                               |       Malignancies, e. g. leukaemia
                  - ----------------------> 2) Phagocytosis---- - 
B.  Genetic Engineering of Blood Cell Lines for Cell-based Therapies:
       Cell Modification                        Cell Modification                 
           Technology:                               Technology:
     (1)         TFs                               (1) Viral Vectors
                    |                                        Tempered:                                            
                    |                                                |
                    |                                  (a) Constructed with
                   V                                       Receptors to Foreign                        
    (2) Blood Cell Line A                       Peptide Antigen from
         Transfusion                                Tumour Cell Biopsy
         (Scalable)                                   (see (3) below)
                    |                                  (b) Constructed with
                    |                                       Coat protein containing
                    |                                       the Foreign Peptide
                    |                                       Antigen
   (3) Neurohormonal                     (c) Enhancement with Multiple
        Expression &                              Viral Vectors due to MHC restriction
        Secretion                               (d) Programmed to be quiescent until
                    |                                      Stage of Blood Cell Line Transfusions
                    |                                                |           
                    |                                               V
              Boosted                           (2)  Blood Cell Line B
                  DC                                     Express Antigenic
                    |                                       Determinants
    Signal Transduction                        (Quiescent) & Tranfusion Scalable
            Pathways:                                       |
                    |                                               | (Transfects)
   (1) Th cell activation                                V
   (2) Th cell expansion                 (3) (a) Tumour-Specific Cells &
   (3) Th differentiation                                |
         to cell line (specific)                  (b) Indications (e. g. malignancies)
   (4) Tc cell antigenic deter-                       |
         minant expansion                              |
                    |                                             V
                    |                               Boosted Expression of Antigenic Determinants
                    - ----------------------->on Cancer Cell Surface (in X103 scale)
                                                    Grandfathered Technoloies
                                                    (Use of various proprietary technologies, e. g.
                                                    CAR-T (R) Cell Technologies with T cells by
                                                    MaxCyte (R), Gaithersburg, MD
                                                    Cytolysis via               Apoptosis of Multiple Solid Cancerous
                                                    Opsonization---------> Tumours / Malignancies, e. g. leukaemia
                                                    is Considerably
(c) D. A. Flores. 2018. Skye Blue Publications. Port Coquitlam. British Columbia CANADA V3B1G3


Drug Discovery with Boosted Dairy Lactoferrin Using Small Molecule Biopharma for Heart Health.

It was quoted recently from a paper that, "The question that confronts the issue of manipulating dairy lactoferrin in milk in terms of composition (and as it would also follow, total output), significantly boost medicinal-conferring milk food proteins (e. g. casein, alpha-lactalbumin and lactoferrin are examples of those of interest in the scientific literature) which likely serve a protective role against chronic inflammation, is with what therapeutic drug discovery using small molecular tools can we carry our search further with?" [D. A. Flores. 2016. Editorial. Biomolecular and Medicine J. @ dannflores9. wordpress.com.] It is believed at Skye Blue that small molecular analogues to p38, a molecule that addresses the 'suite' of chronic inflammatory markers [D. A. Flores. 2013. Overview Paper. Biomolecular and Medicine J. @ dannflores7.wordpress.com], that are 'recalcitrant' to breakdown could be used therapeutically for heart-health, for example, by single amino acid residue substitutions without affecting tertiary considerations to subunit and allosteric structure or function. A so-called 'proteosis' cascade of events will kinetically determine the half-life given the avidity of binding of p38 as ligand.

Boosting Milk Proteins with Medicinal Properties for Heart Health: the Search for Transcription Factors to Caprine Lactoferrin.

The modern molecular genetics of caprine (goat) dairy function (viz. yield or output, milk content or composition,%) has advanced in recent years with finds elucidating the SNP (single nuclear polymorphisms or mutations) in DNA with chromosomal (c'somal) position (viz. their numbering).  Microsatellite tracts consisting of repetitive DNA sequences with certain DNA motifs are repeated 5-50X (times) with DNA microarrays- point oligo-DNA arrays, as probes binding to cDNA or cRNA called targets that are appropriately labelled, used for fine-mapping quantitative trait loci (QTL) determinations, or how significantly a QTL point locus correlates statistically with a phenotypic parameter. However, there have been limitations from "old school" standpoints regards low resolution limited by the statistical confidence limit intervals to a certain significance level. A recent study reported by Shopen et al. (2011) [in Marcel Amills et al., 2012, Genetic Factors that Regulate Milk Protein and Lipid Composition in Goats, Intech, Chap. 1], demonstrated significant association between loci in c'somal positions: 5, 6, 11, & 14 to milk protein composition. For our purposes at Skye Blue of producing GMO goats with boosted caprine lactoferrin (cLF) milk protein for medicinal purposes, a preliminary find that points to regulatory genes (transcription factors, TFs) is a trans-effect in bovine cattle that could apply to sheep and goats of an SNP locus affecting c'some 11 &14 for alpha-casein unit one protein (a major casein protein) while residing in position c'some 6.

(c) D. A. Flores. 2003-2050. SKYE BLUE INTERNET. Port Coquitlam. BC. Canada V3B 1G3.  All rights reserved. Disclaimer.            

Selected Categories:
Product Company   Service Company
- General
- Services
- Communications

Last update of this entry: August 04, 2022

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2022 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.